Skip to main content
padlock icon - secure page this page is secure

Cost‐utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia

Buy Article:

$59.00 + tax (Refund Policy)

To evaluate the incremental cost‐utility ratio (ICUR) of idelalisib in combination with rituximab (IR) versus rituximab monotherapy (R) in the treatment of patients with relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL), from the Spanish National Health System (NHS) perspective.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: chronic lymphocytic leukaemia; cost‐effectiveness; cost‐utility; idelalisib; rituximab

Document Type: Research Article

Publication date: March 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more